Impaired cytomegalovirus (CMV)-specific cell-mediated immunity (CMV-CMI) is a major cause of CMV reactivation and associated complications in solid-organ transplantation. Reliably assessing CMV-CMI is desirable to individually adjust antiviral and immunosuppressive therapy. This study aimed to evaluate the suitability of T-Track â CMV, a novel IFN-c ELISpot assay based on the stimulation of peripheral blood mononuclear cells with pp65 and IE-I CMV proteins, to monitor CMV-CMI following kidney transplantation. A prospective longitudinal multicenter study was conducted in 86 intermediate-risk renal transplant recipients. CMV-CMI, CMV viral load, and clinical complications were monitored over 6 months post-transplantation. Ninety-five percent and 88-92% ELISpot assays were positive pre-and post-transplantation, respectively. CMV-specific response was reduced following immunosuppressive treatment and increased in patients with graft rejection, indicating the ability of the ELISpot assay to monitor patients' immunosuppressive state. Interestingly, median pp65-specific response was ninefold higher in patients with self-clearing viral load compared to antivirally treated patients prior to first viral load detection (P < 0.001), suggesting that reactivity to pp65 represents a potential immunocompetence marker. Altogether, T-Track â CMV is a highly sensitive IFN-c ELISpot assay, suitable for the immunomonitoring of CMV-seropositive renal transplant recipients, and with a potential use for the risk assessment of CMV-related clinical complications (ClinicalTrials.gov Identifier: NCT02083042).
Introduction
Cytomegalovirus (CMV) infection is one of the most common complications after kidney transplantation [1] [2] [3] . In immunocompetent individuals, CMV-specific cell-mediated immunity (CMI) (thereafter referred to as CMV-CMI) is usually able to control primary and latent CMV infection [4] [5] [6] [7] [8] [9] [10] [11] [12] . Impairment of CMV-CMI in immunocompromised patients, such as renal transplant recipients under immunosuppressive medication, is a major cause for CMV reactivation and related complications [6, [13] [14] [15] [16] [17] [18] . Antiviral drugs are also associated with non-negligible side effects (e.g., nephrotoxicity and bone marrow suppression) and are expensive. Reliable assessment of CMV-CMI and of its functional impairment might help to individually adjust antiviral and immunosuppressive therapy, and thus improve patient care.
A number of assays have been described to monitor CMV-CMI, from CMV epitope-specific CD8 + staining [19, 20] to functional assays monitoring the ex vivo response of CMV-specific effector cells [9, 11, 12, [21] [22] [23] . Several studies investigated the ability of these assays to predict the risk of CMV replication and/or CMV disease after kidney transplantation [2, 6, 17, 21, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . Identifying a consensus between these studies is made difficult by the disparity in capability of the respective CMV-CMI monitoring assays (e.g., the nature of the stimulating antigens and of the monitored CMV-reactive effector cells) and by the absence of standardization in case of in-house assays.
T-Track â CMV is a novel, highly sensitive, and standardized IFN-c enzyme-linked immunosorbent spot (ELISpot) assay measuring the response of a large spectrum of clinically relevant CMV-reactive effector cells (including T helper (Th) cells, cytotoxic T lymphocytes (CTL), as well as natural killer (NK) and natural killer T (NKT)-like cells via bystander activation) to immediate early-1 (IE-1) and phosphoprotein 65 (pp65) antigens [36, 37] . Two recent studies validated its ability to monitor CMV-CMI in nontransplanted subjects [38, 39] . Primary aim of this prospective multicenter study was to determine the suitability and sensitivity of this novel ELISpot assay for the monitoring of CMV-CMI in intermediate-risk (DÀ/R+, D+/R+) renal transplant recipients. Secondary aim was to investigate a possible association between IFN-c ELISpot test results and occurrence of clinical complications posttransplantation.
Patients and methods

Study design and participants
A prospective, longitudinal, observational, multicenter study was conducted in a cohort of 96 intermediate-risk (DÀ/R+, D+/R+) renal transplant recipients over 6 months post-transplantation. Patients receiving a standard immunosuppressive regimen (Table 1) and scheduled for preemptive antiviral therapy were eligible for study participation. Patients were scheduled for one pretransplantation (visit 1) and seven post-transplantation (visits 2-8) visits at 3-week intervals. Unscheduled visits took place in case of suspicion of CMV-related complications (study flowchart shown in Table S1 ).
Additional information, such as ineligibility, study aims, definitions, and ethics committee approvals, may be found in Supporting Information (Appendix S1).
CMV-CMI measurement
Blood collection, peripheral blood mononuclear cell (PBMC) isolation, and T-Track â CMV assays (Lophius Biosciences GmbH, Regensburg, Germany) were performed as previously described [37, 39] , and as detailed in Supporting Information (Appendix S1).
Viral load measurement
Cytomegalovirus load in blood was evaluated either by quantitative PCR (CMV DNAemia) or by immunocytochemistry (pp65 antigenemia), as detailed in Supporting Information (Appendix S1). 
Other variables
Cytomegalovirus-related clinical complications, that is CMV syndrome and end-organ CMV disease [3, 40, 41] , were documented together with occurrence of opportunistic infections (BKV, urinary tract infection, bacteria, fungi, EBV, other), graft dysfunction (rejection or loss), and death. Diagnosis of graft rejection was biopsy-based and followed the Banff classification of renal allograft pathology [42] .
Statistical analysis
Calculations were performed with SAS 9.4 Software, and figures were generated using GRAPHPAD PRISM, as detailed in Supporting Information (Appendix S1). Differences in IE-1-and pp65-specific spot-forming cell (SFC) distributions between groups with independent samples were tested using the nonparametric two-sided MannWhitney U (MWU) test. Comparison of groups with paired samples was performed using the nonparametric two-sided Wilcoxon signed-rank test. In case of comparison of groups with multiple measurements per patient, analysis of variance (ANOVA) on ranks tests was conducted, as indicated. Two-sided P-values <0.05 were considered statistically significant.
Results
Patient characteristics
Altogether, 96 CMV-seropositive patients with end-stage renal failure were enrolled in the study prior to or following kidney transplantation. Ten of the 96 intermediaterisk (DÀ/R+, D+/R+) renal transplant recipients had no ELISpot data acquired, as illustrated in the study flow diagram (Fig. S2 ). Blood from the remaining 86 patients was collected to conduct IFN-c ELISpot assays at a minimum of one scheduled visit. Circulating CMV viral load (VL) was determined at most 3-week interval post-transplantation visits. An overview of IE-1-and pp65-specific ELISpot results and of VL levels for the 86 individual patients is presented in Fig. S1 . Patients' demographics, immunosuppressive regimen, transplantation characteristics, and recorded complications are summarized in Table 1 . Of 86 patients, 49 manifested at least one positive VL and 28 experienced at least one CMV complication (positive VL requiring treatment as per investigator's assessment). In four patients, a CMV syndrome was diagnosed, but no end-organ CMV disease occurred. Thirty-eight patients experienced infections other than CMV, and 13 patients showed at least one graft rejection (Table 1) .
IFN-c ELISpot measures CMV-CMI with high sensitivity before and after renal transplantation
The suitability of T-Track â CMV ELISpot assay to monitor CMV-CMI in renal transplant recipients under immunosuppressive therapy was addressed by analyzing IE-1-and pp65-specific SFC levels at all documented visits ( Fig. 1) . SFC levels were highly variable between patients, ranging from 0. (Fig. 1) . Similar patterns were observed in the whole cohort (n = 86; including missing visits) and in the limited set of patients with all eight completed visits (n = 7; data not shown), indicating no major bias due to missing visits. Analysis of qualitative (positive versus negative) test results revealed a proportion of 95% positive tests before transplantation and of 88% to 92% positive tests posttransplantation ( Table 2 ). As previously described [37-39], pp65-specific measurements contributed to the majority of positive test results while IE-1-specific measurements improved the proportion of positive assays by approximately 2-6% points ( Table 2 ). Analysis of ELISpot test results in relation to recipient's HLA class I antigens, notably as to whether associated with the presentation of immunodominant IE-1 and/or pp65 epitopes (Tables S2 and S3 ), demonstrated comparable frequencies of positive test results, regardless of HLA antigens (Table 3) .
Altogether, the IFN-c ELISpot assay can measure CMV-CMI before and after kidney transplantation with high sensitivity and in a HLA-I antigen-independent manner.
CMV-CMI is reduced following treatment with immunosuppressive agents
Treatment with immunosuppressive agents is expected to impair CMV-CMI. Accordingly, median IE-1-and pp65-specific SFC levels decreased by approximately 60% and 40%, respectively (Fig. 1) , and the percentage of IFN-c ELISpot-positive test results diminished by 4 percentage points, from 95% to 91% (Table 2) between visit 1 and visit 2.
To further assess the effect of immunosuppressive therapy on IFN-c ELISpot test results, post-transplantation IE-1-and pp65-specific SFC levels were compared before and after treatment with high-dose steroid. Median IE-1-and pp65-specific SFC were globally reduced by approximately 60% and 40%, respectively, at visits following treatment with ≥1 mg/kg prednisolone equivalent (Fig. 2a) . Analysis of after-to-before ratios of paired samples confirmed a decrease in SFC levels, consistently detected in 19 of 27 (70%) and 20 of 26 (77%) of IE-1 and pp65 stimulations, respectively (Fig. 2b) . A reduction (30-40%) in SFC levels was even detectable in patients under high-dose (≥10 mg) steroid compared to patients under low-dose (<10 mg) steroid (Fig. 2c ). These observations indicate that the ELISpot assay can monitor a functional impairment in CMV-CMI induced by immunosuppressive agents.
CMV-CMI is increased following occurrence of CMV events
Cytomegalovirus-CMI in CMV-seropositive immunocompetent subjects is expected to be boosted following a new encounter with CMV or following CMV reactivation, via the in vivo stimulation of CMV-reactive memory T cells and of the innate arm of cellular immunity [4, [6] [7] [8] 36, [43] [44] [45] [46] [47] . To determine whether activation of cell-mediated immunity in immunosuppressed CMV-seropositive renal transplant recipients can be monitored by T-Track â CMV, IE-1-and pp65-specific SFC levels were examined at post-transplantation visits affected by CMV complications (i.e., positive viral load requiring treatment) and at visits following CMV complications. Median IE-1-specific SFC was approximately 4 times higher at visits documented with CMV complications (44 vs. 12 SFC/ 200 000 cells; MWU P = 0.007; ANOVA on ranks P = 0.038), while median pp65-specific SFC levels were comparable at visits with and without CMV events (116 vs. 151 SFC/200 000 cells, respectively; MWU P = 0.497) (Fig. 3a) . On the other hand, IE-1-and pp65-specific test results were increased in 11 of 14 (79%) and 12 of 14 (86%) of paired samples, respectively, following CMV complications, with median ratios after-to-before CMV complication of 1.8 (Wilcoxon signed-rank test, P = 0.009) and 2.4 (Wilcoxon signed-rank test, P = 0.007), for IE-1 and pp65, respectively (Fig. 3b ). These observations suggest that the IFN-c ELISpot assay can monitor changes in CMV-CMI consecutive to manifestations of CMV complications, upon ex vivo stimulation of PBMC with IE-1 and pp65 antigens.
Elevated CMV-CMI is associated with occurrence of graft rejection
Cytomegalovirus infection has been associated with increased allograft rejection following solid-organ transplantation (SOT) [48] [49] [50] [51] . In this cohort, 15 rejection episodes (in 13 patients) were documented ( Table 1) . Of 15 rejection events, 14 were not associated with detection of positive VL at the visit prior to or at visit of rejection (data not shown), suggesting no association between CMV infection and graft rejection. Another cause for graft rejection is under-immunosuppression, for instance due to strong baseline immunity and/or poor responsiveness to immunosuppressive therapy [52] . According to the Banff classification [42] , eight cases of T-cell-mediated rejections (TCMR) and five borderline changes (defined as suspicious for TCMR) were documented (Table 1) , suggesting an association (100) CMV, cytomegalovirus.
*Defined as at least one epitope for IE-1 (IE-1-specific SFC), for pp65 (pp65-specific SFC), and for IE-1 and/or pp65 (T-Track â CMV) (see Tables S2 and S3) . of graft rejection with cellular immunity. Interestingly, median IE-1-and pp65-specific SFC counts were approximately sixfold and threefold higher, respectively, at visits with future (within the next 6 weeks) graft rejection compared to those with no future graft rejection ( Fig. 4a ; n = 8). Moreover, among the 13 patients who experienced graft rejections, those with TCMR consistently showed higher IE-1-and pp65-specific CMI at any visit prior to and including the visit with documented TCMR, compared to visits with other types of rejection (Fig. 4b) . IE-1-and pp65-specific CMI reached high median SFC counts (330 and 619 SFC/200 000 cells, respectively) in association with future TCMR (Fig. 4b) . Notably, the analysis of paired IE-1-and pp65-specific results revealed a higher proportion (14/ 18 or 78%) of double-positive test results in association n = 34 n = 38 n = 34 n = 37
Figure 2 IE-1-and pp65-specific cell-mediated immunity (CMI) is reduced upon high-dose steroid treatment. The effect of high-dose steroid treatment on IE-1-and pp65-specific ELISpot results post-transplantation (visits 2-8) was analyzed by comparing spot-forming cell (SFC) levels before and after treatment with ≥1 mg/kg steroid (a, b) and by comparing SFC levels at visits affected by treatment with < and ≥10 mg steroid (c). IE-1-and pp65-specific ELISpot results at any visits before and after high-dose steroid treatment are represented as box plots (a) as well as spaghetti plots of paired visits (b). In (b), "After/Before" median ratios of IE-1-and pp65-specific CMI were tested against the hypothetical value of 1.0 using the nonparametric paired Wilcoxon signed-rank test. In (c), differences in IE-1-and pp65-specific CMI between visits under lower and higher steroid doses were tested using the nonparametric Mann-Whitney U test. However, P values should be considered with caution given the bias introduced by the existence of multiple visits with high-dose steroid per patient. Indicated n values represent the number of measurements (a, c) and of paired measurements (b). with future TCMR, compared to TCMR-independent rejection (1/6 or 17%) (Fig. S3) . Altogether, these observations indicate that the IFN-c ELISpot detects elevated CMV-CMI in association with allograft rejection, and more particularly T-cell-mediated rejection.
Reduced pp65-specific CMI is associated with occurrence of opportunistic infections Opportunistic infections (OI) are a common cause of clinical complications following SOT [3, 49] . Among them, BK virus (BKV) infection, responsible for BKV nephritis, is a frequent cause of impaired renal function in kidney transplant recipients [53] . OI mainly occur as a consequence of immunosuppressive therapy (overimmunosuppression) [54] . In addition, CMV infection itself is associated with increased OI incidence [3, 49, 54] . In this study, 38 patients were subject to infections other than CMV (51 events), and nine patients manifested one episode of BKV infection (Table 1) . Thirtyfour of 51 (67%) infection episodes took place in patients with positive CMV VL. However, the time frame of occurrence of other versus CMV infections was distinct (11/34 or 32% within À1 to +1 week of CMV infection). These findings indicate a general susceptibility to infection rather than a close association with CMV infection. No association with CMV infection was observed in case of BKV alone (five of nine or 56% BKV infections in patients with CMV infection), maybe due to the small case number. Interestingly, clearance of BKV infection is known to be strongly dependent on cellular immunity [53, 55, 56] . The analysis of pp65-specific reactivity after kidney transplantation in relation to the occurrence of BKV and of any infection at current or at future (within the next 6 weeks) visits revealed that median pp65-specific SFC values were decreased by 50-80% in association with BKV and any infections (ranging from 158-170 to 28-91 SFC/ 200 000 cells in the absence and presence, respectively, of current or future infection) (Fig. 5) . Differences in IE-1-and pp65-specific CMI between groups with (Yes) and without (No) CMV complication were tested using the nonparametric Mann-Whitney U test. However, p values should be taken with caution given the bias introduced by the consideration of multiple visits affected by a CMV event per patient. An ANOVA on ranks statistical test taking into account multiple measurements resulted in P = 0.038 and P = 0.725 for IE-1-and pp65-specific CMI in "No" versus "Yes," respectively. Median IE-1-specific CMI was 3.8 times higher at visits with CMV complications (MWU P = 0.007; ANOVA on ranks P = 0.038). (b) IE-1-and pp65-specific CMI at paired "Before" and "After" visits with documented CMV events. N values in the table indicate the number of paired measurements. "After/Before" median ratios of IE-1-and pp65-specific CMI were tested against the hypothetical value of 1.0 using the nonparametric paired Wilcoxon signed-rank test (P = 0.009 and P = 0.007, respectively). Of note, 28 patients experienced CMV complications (Table 1) In terms of patient management, one expects from a diagnostic assay to assist clinicians in decision-making for the treatment of patients at risk of developing CMV disease. Due to the absence of documented CMV disease in this cohort, post hoc analyses were conducted, investigating CMV-CMI in relation to CMV reactivation (existence of positive VL). Patients with positive VL and who did not receive antiviral treatment (self-limiting CMV reactivation) were extracted from the initial "no CMV event" group, thus defining three groups: (i) patients with VL = 0 (untreated), (ii) patients with VL > 0, untreated (self-limiting CMV reactivation), and (iii) patients with VL > 0 and antivirally treated (i.e., "CMV event" group). From the full analysis set (n = 86), five patients from the "untreated" category but who incidentally received antiviral prophylaxis (Fig. S2 ) and two patients with no documented VL measurements were excluded (post hoc analysis on n = 79 patients).
As a general comment, the mean age (AESD) of patients without versus with CMV infection post-transplantation was 48.5 (AE12.8) vs. 57.6 (AE6.5) years (MWU; P = 0.022) and correlated with higher median SFC counts (18.33 vs. 36.52 for IE-1 and 177.3 vs. 351.4 for pp65) pretransplant, although the difference was not statistically significant (MWU; P = 0.339 for IE-1 and P = 0.285 for pp65). This suggests that the higher SFC count pretransplantation might be due to CMV-triggered age-related T-cell inflation.
Interestingly, two of two (100%) patients with selfcleared VL post-transplantation had double-positive (IE-1 and pp65) ELISpot test results pretransplantation, compared to 12 of 21 (57%) and eight of 11 (73%) in the no and treated VL groups, respectively (Fig. S4a) . Post-transplantation, median IE-1-specific SFC was 5-6 times higher among patients with treated VL ("CMV event") compared to the two other groups (MWU P < 0.001; ANOVA on ranks P = 0.021 between untreated and treated VL), despite broad SFC distribution in all three groups (Fig. S4b) . This difference indicates significant changes in the response of IE-1-reactive effector cells in patients with higher VL. Remarkably, median pp65-specific CMI was highest in patients with selfcleared VL, both before and after transplantation (Fig. S4a,b) . Similarly, median pp65-specific SFC among patients with self-limiting VL was approximately twofold higher at visits with no VL detection (457 SFC/ 200 000 cells) compared to visits with positive VL (196 SFC/200 000 cells) (Fig. 6a) . In contrast, median IE-1- (Fig. 6a) . Thus, while IE-1-specific IFN-c ELISpot can monitor changes in the activation of IE-1-reactive cells following CMV replication, IE-1-induced SFC level does not correlate with CMV replication. Figure 5 Decreased pp65-specific cell-mediated immunity (CMI) is associated with occurrence of opportunistic infections. pp65-specific CMI at post-transplantation visits was analyzed in relation to occurrence of either any infection other than cytomegalovirus (CMV) or BK virus (BKV) infection. pp65-CMI is presented at visits affected by infection (a) and at visits not affected by infection with respect to occurrence (Yes) or no occurrence (No) of infection within the next 6 weeks (b). N values represent the number of measurements. As several visits were affected by infection, these analyses take into consideration multiple measurements per patients. Differences in pp65-specific CMI between "Yes" and "No" groups were tested using the nonparametric Mann-Whitney U (MWU) test. P values should be considered with caution given the potential bias resulting from the consideration of several measurements per patient. ANOVA on ranks tests taking into account multiple measurements yielded P values >0.05. Occurrence of any infection other than CMV or of BKV infection at current visit or in the future was consistently associated with a 46.3-82.5% decrease in median pp65-specific CMI. . N values represent the number of measurements. This analysis includes several visits per patients, possibly introducing a bias in the group comparison using a MWU test. An ANOVA on ranks test taking into account multiple measurements resulted in P = 0.031 and P = 0.625 for IE-1-and pp65-specific CMI in "No" versus "Yes," respectively. (b) IE-1-and pp65-specific CMI at visit preceding first detection of VL in untreated patients ("self-limiting VL"; white boxes) versus antivirally treated patients ("CMV event" definition; gray boxes). This analysis considers no more than one measurement per patient and is therefore devoid of the bias associated with the consideration of multiple measurements per patient. Groups were compared using a MWU test. Median pp65-specific CMI was 8.8 times higher in patients with self-limiting VL at the visit preceding first occurrence of VL (P < 0.001). Additionally, median pp65-specific SFC inversely correlated with VL levels (Fig. S5 ). These observations suggest that pp65-specific CMI might be a marker of immunocompetence.
BKV Any infection
Transplant Finally, the potential prognostic value of the ELISpot assay was evaluated by assessing IE-1-and pp65-specific SFC distributions at the visit preceding the first detection of positive VL among patients with selflimiting VL versus those treated with antivirals ("CMV event" group). As before, IE-1-specific SFC distribution was wide and skewed in both groups of patients with CMV reactivation prior to first detection of VL (Fig. 6b) . In addition, IE-1-specific SFC levels in these two groups did not correlate with VL levels (Fig. S5) , indicating that IE-1-specific test results prior to detection of CMV replication reflect broad changes in the response of IE-1-reactive cells but is not predictive of CMV reactivation. Strikingly however, pp65-specific SFC levels were ninefold higher in patients with selfcontrolled VL (median 534 SFC/200 000 cells, range 80-982; n = 10) compared to patients with treated VL (median 60 SFC/200 000 cells, range 0.1-751; n = 18) (MWU P < 0.001) prior to first detection of VL (Fig. 6b) . In addition, pp65-specific SFC levels were inversely correlated to VL levels (Fig. S5) . Remarkably, the proportion of patients showing a pp65-specific CMI above the arbitrary value of 100 SFC/200 000 lymphocytes ( Fig. S5 ; red dashed line) was 9/10 (90%) among patients with self-controlled CMV reactivation (VL < center-specific limit), 3/8 (38%) among treated patients with VL < center-specific limit, and 1/10 (10%) among treated patients with VL > centerspecific limit (Fig. S5) .
Discussion
This study describes the IFN-c ELISpot T-Track
â CMV as a highly sensitive and suitable assay to monitor CMV-CMI in immunocompromised renal transplant recipients. This high proportion of positive test results is likely due to the stimulation of a broad spectrum of CMV-specific effector cells by T-activated â antigens, combined with the consideration of both pp65-and IE-1-specific responses [36, 37, 39, 57] . The immunosuppressive state is determinant in defining clinical outcomes in SOT recipients. This "net state of immunosuppression" [54] is the result of the balance between overimmunosuppression, resulting in infections such as CMV, and underimmunosuppression, associated with increased risk of graft rejection or loss. Proper evaluation and monitoring of patients' immunosuppressive state are therefore critical. IFN-c ELISpot SFC levels were consistently reduced following immunosuppressive therapy, demonstrating the assay's ability to monitor the response of patients to immunosuppression. On the other hand, IFN-c ELISpot test results were increased in most patients following CMV reactivation, as expected from the reactivation of CMV-specific memory T cells. Increased pp65-specific CMI after but not at visits affected by CMV events, as opposed to IE-1-specific CMI, might reflect the kinetics of CMV reactivation, IE-1 being an immediate-early gene and acknowledged marker of early CMV reactivation as opposed to the late antigen pp65 [10, 58, 59] . It might additionally reflect the dynamics of IE-1-and pp65-specific CD8 + and CD4 + T-cell responses during CMV infection and reactivation [6] [7] [8] 10] . That most patients were responders in the ELISpot assay correlated nicely with the absence of clinical outcome in this cohort, further suggesting that the majority of patients still presented a protective immunity against CMV. Likewise, this finding indicates that the IFN-c ELISpot assay might identify nonresponders as patients potentially over-immunosuppressed. Conversely, ELISpot test results were increased prior to graft rejection. As 13 of 15 (87%) of graft rejection episodes were attributed to or suspicious for TCMR, the ELISpot assay might be able to monitor strong cellular immunity in potentially under-immunosuppressed patients. The absence of standardized immunosuppressive therapy in this study did not allow to directly address whether immunosuppressant doses correlated to the occurrence of infections and graft rejections. Finally, changes in CMV-CMI in relation to occurrence of opportunistic infections were similar to those detected in association with CMVrelated complications, indicating that IFN-c ELISpot results, notably in response to pp65, might not only reflect CMV-CMI but more globally the patient's immunocompetence status and susceptibility to infection.
Altogether, these analyses demonstrate that T-Track â CMV is a sensitive assay enabling the monitoring of the immune status of renal transplant recipients. Additional studies will be necessary to determine whether it might assist clinicians in their decision to adjust immunosuppressive therapy. Interestingly, a randomized, prospective study is currently assessing the ability of measuring CMV-specific T cells to steer immunosuppressive therapy in pediatric kidney transplant recipients [60] . An essential goal of a CMV-CMI monitoring assay is to enable risk stratification of future CMV-related complications in order to improve clinical management of patients. Due to the absence of documented CMV disease in this cohort, a clinical cutoff could not be defined. Instead, ELISpot results were analyzed in terms of prediction of spontaneous clearance of CMV viral load (VL) among patients with CMV reactivation. It should be emphasized that the comparison of patients with self-cleared VL to those with treated VL was in part biased by the fact that a number of treated patients with low VL might have undergone self-clearance in the absence of treatment (Patient 037 in Fig. S1 might be one such example). Nevertheless, we observed significantly higher pp65-specific SFC counts in patients with self-limiting VL (n = 10) compared to antivirally treated patients (n = 18) at the visit preceding the first detection of VL (P < 0.001), supporting the proposition that pp65-specific SFC is a marker of immunocompetence. Interestingly, 90% (9/10) of patients with selfcleared VL had pp65-specific test results above 100 SFC/200 000 lymphocytes at the visit preceding first detection of VL, as opposed to 22% (4/18) among antivirally treated patients. Additional studies should be performed, including high-risk renal transplant recipients, to confirm this observation and identify a potential clinical cutoff of protection against CMV-related clinical complications. Supporting the proposition that pp65-specific IFN-c ELISpot results mirror CMV-CMI, pp65-specific SFC prior to first detection of VL negatively correlated with VL level, in agreement with reports of an inverse correlation between CMV-CMI and CMV viremia in renal transplant recipients [13, 15, 21] .
As opposed to pp65, IE-1-specific SFC levels posttransplantation did not correlate with VL levels and did not mirror CMV-CMI, although significant changes in IE-1-specific ELISpot test results were observed following CMV reactivation. Accordingly, while pp65-specific SFC levels remained relatively stable over time at the level of individual patients, IE-1-specific SFC showed greater variability (e.g., patients 020, 058, 082, or 096; Fig. S1 ). These broad changes likely reflect the dynamics and kinetics of response of IE-1-responsive effector cells characteristic of CMV infection and/or reactivation [6] [7] [8] 10, 11, 28, 58, 59, 61] , and might explain the lack of predictive value of the response to IE-1 antigen noted in this study. Further investigations are necessary to determine whether monitoring CMV-CMI more frequently might reveal a predictive value of IE-1-induced ELISpot results.
On the other hand, pretransplantation IE-1-specific response, together with pp65-specific response, might have some predictive value for self-cleared viremia post-transplantation, based on our observation that both patients with self-limited VL whom were tested in ELISpot before transplantation showed double-positive 
T-Track
â CMV in renal transplantation study, in the collection, analysis, and interpretation of data, and in the writing of the manuscript. 
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